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Abstract
Background: Various treatment methods are used to deal with sexual problems.
Objective: This study was applied to answer the question of whether psychosexual
therapy (PST) can be a reliable alternative to bupropion extended-release (BUP ER) to
promote sexual function in infertile women.
Materials and Methods: In this randomized clinical trial, 105 infertile womenwith sexual
dysfunctionwere randomly allocated to three groups: PST, BUP ER, and a control group.
The PST group participated in a total of eight 2-hr group sessions. In BUP ER group,
150 mg/day Bupropion ER was administered for eight weeks. The control group did
not receive any interventions. The female sexual function index (FSFI) and a clinical
interview were used to assess their sexual dysfunction.
Results: The mean pre-to-post treatment scores of FSFI and its subscales increased
significantly in PST and BUP ER groups (except in the subscale of sexual pain) (p =
0.0001, p = 0.0001). The changes in the subjects were not significant in the control
group. After adjusting for the baseline values, the results remained significant for the
mean FSFI (p = 0.0001), and its subscales between the groups. Compared to the control
group, a significant increase was observed in the mean FSFI (p = 0.0001, p = 0.002)
and its subscales in the PST group and in the BUP ER group (except in the subscale of
sexual pain). Comparison of two intervention methods showed that PST had the better
effect on the sexual function improving (p = 0.0001) and its subscales (exempting the
subscale of orgasm) than BUP ER.
Conclusion: PST can be considered not only a reliable alternative to pharmacotherapy;
it also produces better results in terms of improving sexual function in infertile women.
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1. Introduction
Sexuality is an important part of health and the
main subject in quality of life studies (1). Sexual
health is defined as the “ability to have enjoyable
and safe sex life” (2). The cycle of a woman’s sexual
response is mainly affected by psychological,
social, and physical factors (3). Female sexual
dysfunction (SD) is a common health problem
(4) that includes female sexual interest/arousal
disorder, female orgasmic disorder, and genito-
pelvic pain/penetration disorder (5). Reviews
of the literature showed that approximately
30–50% of women have sexual complaints (1).
SDs are particularly common among infertile
women. A recent study reported the prevalence
of SDs as 46.6% in a sample of healthy Iranian
infertile women. Infertility is a stressful and
difficult phenomenon and may also become a
source of SD (4), although, it is equally probable
that sexual problems directly affect infertility
by decreasing the intercourse frequency (6).
SD is a widespread health problem calling for
effective treatment options (4, 7). Studies reveal
that both psychotherapy and pharmacotherapy
can improve sexual problems. The sex therapy
approach of Masters and Johnson was the
first psychological intervention (encompassing
counseling, psychosexual education, behavioral
exercises, and sensate focus) that facilitated the
re-experience of sexual pleasure (8). Franken
proposed that sexual interventions can promote
safe sex, give rise to sexual identity, and prevent
SD (9). Studies have provided supporting pieces
of evidence on the benefits of bupropion for SD
(10, 11). This medication has been proven effective
in the treatment of the clinical signs of female
SD (11, 12) and has improved sexual functioning
in 29% of non-depressed women with hypoactive
sexual desire disorder within a matter of a few
weeks (13). Furthermore, a study has shown the
benefit of bupropion as an antidepressant in
women who are depressed or who have selective
serotonin reuptake inhibitors -induced SD (10).
Primarily, bupropion is a dopamine agonist and
raises the dopamine level, which is a key mediator
of several human behaviors, including sexual
function (11).
To our knowledge, there are no randomized,
controlled, prospective trials published on the
effectiveness of psychosexual therapy (PST) in
comparison with pharmacotherapy in improving
sexual function in cases of infertility. The
present study was therefore conducted as a
randomized clinical controlled trial to examine
the effectiveness of PST and pharmacotherapy
with bupropion extended-release (BUP ER) in
promoting sexual function in infertile women. The
study hypothesizes that PST is a reliable alternative
to BUP ER for promoting sexual function in infertile
women.
2. Materials and Methods
An open-label randomized, controlled,
clinical trial was conducted in the Infertility and
Reproductive Health Center of Babol University
of Medical Sciences, Babol, Iran, from December
2014 to July 2015. The study is focused on
the comparing of pharmaceutical and non-
pharmaceutical methods in promoting sexual
function in infertile women. Two midwives with
no clinical involvement in the trial enrolled
the participants and assigned them to the
interventions. Our inclusion criteria included
the female sexual function index (FSFI) ≤ 26.55
(Final approval by a female psychologist in
the clinical interview), the infertility duration
more than one year, no intention of infertility
treatment over the next two months, age <
45 yr., reading and writing literacy, having a
stable sexual life (At least for four weeks before
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study), no history of remarriage in husband,
no history of sterilization, and having no foster
children. The infertile women with any of the
following conditions were excluded: history of
hypertension, diabetes mellitus, cardiovascular
disease, hypothyroidism, hyperthyroidism,
epilepsy, spinal cord injury, liver dysfunction,
psychiatric problems under treatment, having
suicidal ideation, taking medications that cause
SD such as barbiturates, benzodiazepines,
antidepressants and antihypertensive drugs,
getting psychological support (such as
psychotherapy sessions, relaxation exercises,
Yoga, and etc.), having a stressful event in the
past three months (serious illness or death in the
family), major changes in living conditions, and
smoking.
In addition, all participants with Beck depression
score ≥ 10, who met the criteria for major
depression in the clinical interview by a
female psychologist, were excluded from the
study and were referred to a psychiatrist for
treatment.
Of the 485 infertile women referred to the
Infertility and Reproductive Health Center from
December 2014 to July 2015, 127were not willing to
participate, 124 met the exclusion criteria, and 129
had no SD. A total of 105 women with SD agreed
to participate in the study and only 99 participants
remained until the end of the study (Figure 1). In this
protocol, both the researcher and the participants
were not blinded. The sample size was calculated
as 23 subjects in each group to yield an 80% power
with 95% Confidence level, accuracy = 6.02, and
approximate standard deviation (SD) = 7.3, based
on previous studies for each group (8, 10, 12-13).
Considering the drop out percentage as 10 % and
using the corrected sample size formula (n’ = Kn,
k = 2) (14), a total of 105 eligible infertile women
were selected equally in three groups (n = 35/each
group).
Computer-aid randomization procedures (by an
investigator with no clinical involvement in the
trial) were used at the beginning of the treatment
phase to allocate the participants in a 1:1:1 ratio
into the three groups of 35 people each – a PST
group, a BUP ER therapy group, and a control
group. The PST group participated in a total of
eight 2-hr group sessions of mindfulness-based
cognitive therapy (MBCT), behavior sex therapy,
and relaxation training presented in the form of
lectures, question and answer, group discussions,
booklets, and CD. There were 9 to 13 members
in each session. The therapeutic model used
was a combination of MBCT (15) and behavior
sex therapy. The sexual behavior program and
the relaxation training sessions were adapted for
infertile women based on the Crowe and Ridley
model and also tranquility books (16, 17).
In BUP ER group, 150 mg/day Bupropion
ER (Wellban External Release, Dr. Abidi
Pharmaceutical Laboratories, Iran) was
administered under the supervision of a
psychiatrist for eight weeks. In previous studies,
the trial length varied from 4 to 24 weeks
with bupropion dosage ranging from 75 to
450 mg/day (10, 12-13, 18, 19). The control
group did not receive any interventions. To
observe the ethics of research, the members
of the control group were referred to a sex
therapy clinic at the end of the eight-week trial
and educational package was given to them.
Regular monitoring of adverse events, height,
body weight, and vital signs were assessed
in each groups by the researcher once every
two weeks. The participants were informed not
to use any other drugs. To answer any further
questions, the researchers gave their phone
numbers to the participants. Also, the researchers
monitored participants for any change in their
health status or for any complaint by phone
weekly.
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A demographic questionnaire was used to
collect participants’ socio-demographic data,
including age, husband’s age, level of education,
and level education of husband, husband’s
occupation, socioeconomic status, duration
of infertility, and the type of infertility. FSFI
questionnaire was also used to collect data
on the participants; this self-report inventory
consists of 19 items and was developed by Rosen
and his colleagues (20). This study used the
culturally adapted Iranian Version of the FSFI
(IV-FSFI). This inventory has six different subscales,
including desire, arousal, lubrication, orgasm,
satisfaction, and pain. The responses to the
items are scored based on a 5-point Likert-type
scale. The total score obtained ranges from 2
to 36. The participants scoring 26.55 or less
are considered “at risk” for SD. A higher FSFI
score indicates a better sexual function. The
reliability of the IV-FSFI has been confirmed
with a Cronbach alpha ranging from 0.79 to
0.86 and the tool has excellent construct validity
as well (4, 20). The BDI is used to assess the
severity of depression symptoms with reliability
(0.96), validity (0.89) in the Iranian population
(21).
Enrollment 
Allocated to intervention PST   (n 
= 35) 
- Received allocated intervention 
(n = 33)  
-Did not receive allocated 
intervention (n = 2) 
1 presented only for one session. 
 1 withdrew consent to 
participate. 
Allocated to intervention BUP 
ER (n = 35) 
-Received allocated intervention 
(n = 33) 
-Did not receive allocated 
intervention (n = 2) 
1 took bupropion for one week. 
1 withdrew consent to participate. 
Allocation 
Assessed for eligibility (n = 485) 
Excluded (n = 380) 
Ø Not meeting inclusion criteria (n = 124) 
Ø Declined to participate (n = 127) 
Ø Other reasons (n = 129) Randomized (n = 105) 
Analysed (n = 35 completed 
at least one efficacy 
assessment and analyzed) 
-Excluded from analysis 
(give reasons) (n = 0) 
Analysis 
Analysed (n = 35 completed at 
least one efficacy assessment 
and analyzed) 
-Excluded from analysis (give 
reasons) (n = 0) 
Allocated to Control group (n= 
35) 
- Received allocated Control 
group (n = 33)  
-Did not receive allocated 
Control group (n = 2) 
2 withdrew consent to 
participate. 
Analysed (n = 35 completed 
at least one efficacy 
assessment and analyzed) 
-Excluded from analysis 
(give reasons) (n =  0) 
Figure 1. The recruitment and randomization of the infertile women in the study group.
2.1. Ethical consideration
The research project has been approved by
the Ethics Committee of the Babol University of
Medical Sciences, Babol, Iran (code: 4930). All
participants were briefed on the study objectives
and methods and were then evaluated to see
whether they met the study inclusion criteria.
Informed written consent forms were obtained
from all the participants. Data were collected
confidentially.
2.2. Statistical analysis
The Chi-squared test, the paired t test, the
Analysis of covariance (ANCOVA), the Multivariate
Analysis of Covariance (MANCOVA), and post-
hoc test were used for analyzing the data.
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Demographic variables were analyzed using
descriptive statistics (i.e., mean and standard
deviation for the quantitative measurements and
percentage for the categorical data). Before-
and-after means comparisons in each group
were made using the paired sample t test.
The mean difference in the sexual function
score was compared using the ANCOVA,
which included region and baseline value as
the covariate. The MANCOVA was used if the
correlation between the FSFI subscales (desire,
arousal, lubrication, orgasm, satisfaction, and
pain) ranged from 0.3 to 0.7. The statistical
procedure assumed randomized sampling, the
normality of distributions, the homogeneity of
variances as per Levene’s F test, and linear
relationship between the dependent variable
and the covariate. Post-hoc test was used
to calculate pairwise comparisons between
groups. The skewness and kurtosis test was
used to evaluate the normality of the continuous
variables. The study population in which data
were analyzed consisted of the intent-to-treat
(ITT) population, that is, of all the patients
randomized to the treatment groups. There
were no differences in the demographic details
and the baseline FSFI and subscale scores in the
subjects who stayed in the study until the end
and those who did not. All the analyses were
performed using the Statistical Package for the
Social Sciences, version 21.0 (SPSS, IBM Crop.,
Armonk, NY, USA). P < 0.05 was considered as
significant.
3. Results
The mean age (±SD) of the subjects and
their husbands was 28.89 ± 5.42 and 32.05
± 5.14 yr., respectively. The majority of the
infertile women and their husbands had a high
school diploma (50.5% and 35.25, respectively).
More husbands had university education than
wives (30.5% vs. 26.7%, respectively; p <
0.001).
The mean duration of infertility was 4.39 ±
3.54 yr (ranging from 2 to 16 yr) in the subjects.
There were no significant differences between
the baseline FSFI and the socio-demographic
data of the three groups in terms of age,
husband’s age, level of education, husband’s level
of education, and the duration of infertility (Table
I)
The results of the present study showed
significant differences in the mean of FSFI
score between the groups after adjusting for
baseline values in the ANCOVA (p < 0.0001).
The research assumption about the effect
of the therapeutic intervention on FSFI with
a probability value above 99% in infertile
women was thus accepted. The pair-wise
ANCOVA comparison of the post-intervention
FSFI scores showed a significant difference
in PST and BUP ER groups compared to
the control group (p < 0.0001; p = 0.002,
respectively) and also between the treatment
groups themselves as per the post-hoc ANCOVA
(p < 0.0001; Table II). A significant difference
was observed in the mean FSFI subscale scores
between the groups after adjusting for baseline
values in the MANCOVA (desire, excitement,
lubrication, orgasm, satisfaction, p < 00001,
sexual pain; p = 0.002). Table III presents
the adjusted mean (±SD) and MANCOVA of
the dependent variables (desire, excitement,
lubrication, orgasm, satisfaction, and pain).
The pair-wise MANCOVA comparison of the
post-intervention FSFI subscale scores showed
significant differences in the PST and BUP groups
(except in the subscale of pain) compared to the
control group as well as between the treatment
groups themselves (except in the subscale of
orgasm).
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The mean (±SD) of the FSFI score was
22.86 ± 2.29 in infertile women. The mean
and standard deviation of the FSFI score was
22.56 ± 2.36 at baseline and 27.73 ± 3.78
after the intervention in treatment groups (PST,
BUP ER; p < 0.0001) (Table II). The paired t test
showed significant changes in mean pre-to-
post treatment scores of FSFI (p < 0.0001) and
the scores obtained in the subscales of desire,
arousal, lubrication, orgasm, and satisfaction
in both the PST and the BUP groups (p <
0.0001). The changes in the subjects were not
significant in the control group. A comparison
of the mean baseline and post-intervention
scores of the subscale of pain using the paired
t test showed a decreased pain in the PST
group (p < 0.0001). The changes in the subjects
were not significant in the BUP (p = 0.315) and
control (p = 0.245) groups. BUP ER was well
tolerated.
Table I. The sociodemographic characteristics of the study participants
Variable All (n = 105) Treatment groups (n = 35/each)
PST BUP ER Control P-value
Age (yr)* 28.89 ± 5.42 30.00 ± 5.23 27.31 ± 5.22 29.34 ± 5.58 0.096
Age of husband (yr)* 32.05 ± 5.14 33.11 ± 5.68 30.60 ± 3.59 32.43 ± 5.68 0.106
Infertility duration (yr)* 4.39 ± 3.54 4.11 ± 3.55 4.97 ± 3.39 4.09 ± 3.68 0.497
Educational level**
< Diploma 24 (22.9) 10 (28.6) 10 (28.6) 4 (11.4)
Diploma 53 (50.5) 17 (48.6) 18 (51.4) 18 (51.4)
College education 28 (26.7) 8 (22.9) 7 (20.2) 13 (37.1)
0.262
Husband educational level**
< Diploma 36 (34.3) 12 (34.3) 12 (34.3) 12 (34.3)
Diploma 37 (35.2) 15 (42.9) 12 (34.3) 10 (28.6)
College education 32 (30.5) 8 (22.9) 11 (31.4) 13 (37.1)
0.696
*Data presented as Mean ± SD. ANOVA was performed to compare the mean scores of groups
**Data presented as n (%). A Chi-square test was performed to compare the frequencies of groups
PST: Psychosexual therapy; BUP ER: Bupropion extended-release
Table II. Adjusted mean (SD) and analysis of covariance of FSFI in the groups









PST BUP ER Control













530.565 265.283 2 25.982 0.999 0.0001
Pair wise comparisons
Group PST vs control PST vs BUP ER BUP ER vs Control
P-value P-value P-value
FSFI 0.0001 0.0001 0.002
FSFI: Female sexual function; PST: Psychosexual therapy; BUP ER: Bupropion extended-release
Note. Comparing the change in the pre- and post-mean FSFI score, the difference was significant in each treatment groups
(PST; p < 0.0001 and BUP; p < 0.0001), but not in the control group (p = 0.185) (Paired t test)
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Table III. Adjusted mean (SD) and multivariate analysis of covariance of FSFI domains in the groups
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P-value
PST BUP ER Control















































































13.249 6.625 2 6.567 0.902 0.002
Pair-wise comparisons
Subscales PST vs Control PST vs BUP ER BUP ER vs control
P-value P-value P-value
Desire 0.0001 0.028 0.009
Excitement 0.0001 0.007 0.004
Lubrication 0.0001 0.019 0.031
Orgasm 0.0001 0.070 0.005
Satisfaction 0.0001 0.024 0.037
Pain 0.003 0.002 0.938
PST: Psychosexual therapy; BUP ER: Bupropion extended-release
Note. The paired t test showed significant changes in the mean pre-to-post treatment scores obtained in the subscales of FSFI
in the PST and BUP ER (except in the subscale of sexual pain) (p < 0.0001), but not in the control group
4. Discussion
The results of the present study revealed a
significant difference in the post-intervention
score of FSFI and its subscales (desire, arousal,
lubrication, orgasm, satisfaction, and pain) between
the three groups after adjusting for baseline values.
The increasing scores were more significant in the
treatment groups compared to the control group.
SD is prevalent in infertile women and calls for the
design of effective treatment options (7). Female
sexuality can be affected by psychological and
physical factors (3); therefore; psychotherapy and
medical treatment can both be suitable choices
for reducing sexual concerns (8). Psychotherapy,
targeted sexual therapy, and pharmacologic
treatments are the currently available interventions
for the management of SD in women (22).
Studies have revealed pharmacological and
non-pharmacological interventions such as sex
education programs, cognitive behavioral therapy
(CBT), and chemical pharmacotherapy to be
associated with greater marital satisfaction and
improved sex life (19, 23).
The present study found that eight weeks of
PST yields statistically and clinically significant
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improvements in sexual function compared to
when no interventions are performed. The analysis
of the pre-to-post interventions data showed
significant changes in sexual function scores in the
PST group, whereas this changewas not significant
in the control group. Fruhauf and her colleagues
found that psychosexual interventions can help
promote sexual function and as such constitute
a promising treatment option (8). Psychotherapy
or sexual therapy is beneficial for SD in women
and sex therapy appears to be an effective
treatment option for improving sex life (24). PST
is therefore helpful and necessary, especially for
infertile women.
According to the findings, PST had a significant
effect on all the subscales of desire, excitement,
lubricant, orgasm, satisfaction, and pain compared
to the control group. A comparison of the mean
baseline and post-intervention subscale scores
of FSFI in the PST group showed an increasing
trend. There were no significant changes in the
FSFI subscale scores in the control group. A
review of the literature showed that psychological
interventions increase sexual desire, orgasm, and
sexual satisfaction and decline the symptoms
of SD (8, 24). In a review study, Fuql-Meyer and
colleagues recommended the comprehensive
somato-psychological multidisciplinary approach
for the management of female genital sexual
pain (25). Sex education programs significantly
improved the overall score of sexual function as
well as the scores of all its subscales, including
desire, excitement, lubrication, and satisfaction
(23). Mohammadi and colleagues showed that
sexual skills training helps increase women’s
marital satisfaction (26). In a trial study conducted
by Eshghi and colleagues, sexual CBT for couples
helped to improve hypoactive sexual desire
disorder in women (27), while in another study, no
significant changes were observed in the subjects
in the subscales of orgasm and pain after receiving
a sex education intervention (23).
The results of the present study showed a
significant improvement in sexual function in the
BUP ER group compared to the control group.
The findings showed that the pre-to-post treatment
sexual function score changed significantly in the
subjects in the BUP ER group, whereas these
changes were not significant in the control group.
In linewith these findings, Ginzburg and colleagues
also reviewed studies published in Medline from
1970 to 2005 and found that bupropion has a
favorable effect on SD (19). In a double-blind
multicenter study, Thase and colleagues found
that the total score of sexual function increases
after a regimen of bupropion (28). A number of
trial studies have also shown that bupropion may
be a promising medication for the treatment of
sexual problems (12, 19). Koshino and colleagues,
however, reported no significant changes in the
subjects treated with bupropion in regard to SD,
which is inconsistent with the present findings
(29). Bupropion is a dopamine agonist and raises
dopamine levels. A dopaminergic pathway is
essential to physiological mating behavior. A
review of the literature found that pharmacological
agents with central mechanisms of action or
androgenic effects can be a good option for
the treatment of different aspects of female SD
(12). The effect of bupropion on sexual function
is attributed to how it increases dopaminergic
and noradrenergic transmission (11). Moreover,
there was a significant improvement depression
symptom. Lower depression score associated
with higher sexual function. As bupropion is an
antidepressant, it is therefore important to note that
the promotion of sexual function may relate with
a resolution of depression scores in a patient with
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SD (18), since depression and sexual problems are
interchangeable with each other and treatment of
one will change the others.
The obtained data revealed statistically
significant improvements in sexual desire, arousal,
lubrication, satisfaction, and orgasm (but not in
pain) in the BUP ER group compared to the control
group. In addition, a comparison of the mean
baseline and post-intervention FSFI subscale
scores showed an increase in all the subscales of
FSFI (except in the subscale of pain) as the control
group showed no significant changes in the mean
FSFI subscale scores, which is nearly consistent
with the results of previous studies on the subject
(12, 13). A review of the literature showed that
bupropion can be a promising medication for SD
(19). An increase in sexual libido and arousal was
reported in other studies following the use of this
medication (10, 12, 18). Bupropion was also effective
in treating hypoactive sexual desire disorder in
women (10, 13, 30). Croft and colleagues, however,
conducted a placebo-controlled trial and showed
no statistically significant differences in sexual
satisfaction between the placebo and bupropion
groups after one week of treatment, and by
the end of the study, the percentage of sexual
satisfaction was similar in the placebo group
and the bupropion group (18). Due to the lack
of changes in the orgasm subscale, it can be
concluded that reaching orgasm is a skill that
requires practice, more time, and long-term
medication, which may be beyond the short scope
of this study and its short treatment periods. In one
study, Pereira and colleagues found that diffuse
long-term pain is more difficult to treat (30). Further
studies need to detect factors contributing to the
lack of an effect in the orgasm subscale.
According to the findings, the PST group showed
superior results to the BUP ER group in terms of
improved FSFI and subscale scores, exempting
the subscale of orgasm. The mean total FSFI and
subscale (desire, arousal, lubrication, satisfaction,
and pain) scores were significantly higher in the
PST group compared to the BUP ER group at the
end of the study. A similar study showed that sexual
and marital problems improve more extensively
with CBT than with pharmacotherapy. CBT is,
therefore, a reliable and superior alternative
to pharmacotherapy in reducing sexual and
marital concern in infertile women (31). Another
study showed that psychological interventions
are a promising treatment for sexual problems
compared to pharmacological treatments and
have two principal benefits, including a lack of
physical side effects and the re-establishment
of sexual function beyond a mere reduction of
symptoms (7). Shams Mofaraheh and colleagues
proposed marital counseling with sex education
as one of the most effective treatment options for
promoting sexual satisfaction and improving the
quality of sex life (32). There is still no consensus
on the effectiveness of pharmacotherapy and
medications such as bupropion cost more than
expected and are also associated with common
adverse effects such as dry mouth, headache,
nausea, and insomnia (12); as chemical options
pose side effects, it is better to seek a second
clinical opinion before administering them for
the treatment of SD. Treatments for sexual
problems can either include non-pharmacological
or pharmacological measures. Among all the
methods, cognitive behavioral measure has been
recognized to be most useful (33), and PST
can thus be regarded as a superior alternative
to pharmacotherapy in the resolution of most
aspects of female SD. Moreover, the present
findings showed a trended significant difference
in the scores of the subscale of orgasm in the
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PST group compared to the BUP ER group;
this difference may be attributed to how PST
requires a longer time to have its efficacy on
orgasm confirmed. In a review of literature by
Heiman and Meston, physical causes for primary
orgasmic dysfunction were found to be rare and
they can, therefore, be effectively treated through
psychosexual interventions. The majority of the
cases of intermittent or situational anorgasmia
is attributed to relationship problems and can,
therefore, be resolved with psychotherapy (33).
In a randomized clinical trial study by Pereira and
colleagues, sex therapy was found to lead to
better outcomes for patients with orgasmic and
sexual pain disorder (30). These findings support
the benefits of PST compared to bupropion on
female sexual function and its subscales in healthy
infertile women.
Limitation
There were a number of limitations in this
study protocol. The first limitation was the small
sample size examined; although the select health
center is the only public referral center for infertility
and reproductive health in Babol, Iran; the results
cannot be generalized to the entire population
of infertile women with SD in Iran. Future studies
are therefore recommended to consider the entire
population of infertile Iranian women. The second
limitation was the short period of the study; future
studies need to examine the long-term sexual
effects of psychosexual therapy and bupropion.
The third limitation was that it is not clear whether
or not the different results between the groups
can be attributed to how more time and attention
were given to the group of infertile women in the
PST group. Moreover, the infertile women were
not blinded to their method of intervention and
there were also no placebo groups with which
to compare the results. The researchers thus
recommended double-blind, randomized, placebo-
controlled, clinical trials to be conducted on the
subject in the future. The strengths of this study
include the use of a validated FSFI and a clinical
interview.
5. Conclusion
To conclude, the results of the present controlled
clinical trial showed that PST is superior to
pharmacotherapy with BUP ER in improving sexual
function. Pharmacotherapy with BUP ER is better
than no therapy, although it does not affect pain
during sex. This finding suggests that PST can
be a good alternative for the treatment of infertile
women with SD.
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